Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio

For Immediate Release

Chicago, IL – Feb 26, 2018 – Today, Zacks Investment Ideas feature highlights Features: Alibaba BABA, NVIDIA NVDA, Edwards Lifesciences EW, Sangamo Therapeutics SGMO and bluebird bio BLUE.

Recession Is Coming! Not

The big headline this week for market players was from the chief of the biggest hedge fund in the world, Ray Dalio of Bridgewater, which has AUM (assets under management) north of $150 billion. From Reuters...

Head of world's largest hedge fund says U.S. in a 'pre-bubble phase' with a 70% chance of recession

"I think we are in a pre-bubble stage that could go into a bubble stage," the hedge-fund manager said during a Harvard Kennedy School's Institute of Politics on Wednesday.

Okay, that sounds pretty good for stock investors who know how to play the game. As I've said for years, we ain't near "euphoria" nor "irrational exuberance" yet, so buying the dip in strong growth companies is still the game plan.

But then he throws in the "70% chance of recession" analysis in the same breath?

What Dalio actually said was that he is estimating the probability of a recession by the 2020 presidential election at 70%.

He is also quoted as saying recently "the risks of a recession in the next 18-24 months are rising."

Okay, that also makes more sense. A lot can happen in 2 years. Inflation could spike, sending interest rates higher and inverting the yield curve, one of the classic harbingers of economic recession.

Any reasonable economist or investment asset manager could be modeling a 50% probability of recession in the next 18 months as a "look-out" for unknown unknowns, i.e., "black swans."

Feeling Stupid, or Savvy?

But Dalio is also the same guy who last month told global investors at Davos that "if you're holding cash, you're going to feel pretty stupid" as the stock market was due to rocket to fresh heights.

The next week, the "flash correction" began. I decided I would feel stupid if I didn't have cash for that dip. So we sold some stuff near the highs and bought the lows aggressively. That story here with lots of stock charts.

So what do we do with these big warnings from a hugely successful asset manager?

I believe you need to stay focused on the fundamentals which argue for continued fund flows into equities over the next 18 months.

On October 9, I wrote a special report for Zacks Confidential titled The Monetary Myth of Gold. Here was a good summary of my "better than gold" investment thesis...

If you follow my portfolios, media appearances, or other investment commentary, you know the primary macro themes that have made me stay aggressively long growth and technology stocks this year.

In case you've lost track, I will list a few of them that are extremely relevant...

1) Global economic momentum, however slow & steady it appears

2) Interest rates on our side, as investors in any asset class

3) Technological innovation unleashed in so many industries that the exponential results are staggering

4) Consumer/worker adaptations to rapid change and innovation are astoundingly positive for corps

5) While automation threatens the need for that dastardly concept of Universal Basic Income, tech/science entrepreneurs across the planet continue to create and build wealth for more people around the globe

(end of Zacks Confidential excerpt)

In that report, after giving a detailed explanation -- including inflation, interest rate, and US dollar dynamics -- of why gold was not a favorable choice for our investment capital, I picked 3 growth stocks for Zacks members from Retail, Technology, and Healthcare that I believed would outperform gold over the next 12-18 months.

They wereAlibaba, NVIDIA and Edwards Lifesciences.

After making new all-time highs above $200, Alibaba has fallen back in line with gold and the S&P 500.

Meanwhile NVDA and EW are stealing the show, as strong growth franchises like to do.

And I'm sticking with all 3 names this year. But I have a boatload more ideas that I either own or I'm tracking every week.

For instance, if you believe that this Technology Super Cycle has more room to run, then you'd be a buyer of Lam Research.

And if you like picking Biotech ponies, you might have joined me in our recent 155% gain in Sangamo Therapeutics. Meanwhile we still own bluebird bio from $95 and a handful of other promising Healthcare Innovators.

Bottom line:Let's say Dalio is only half right about all his bold predictions. That means we can bank on stocks continuing to "bubble up" over the next year and we need only keep a vigilant eye on the inflation/rates picture and economic data for early signs of trouble (of which I see few now).

With this strategy, I don't plan on feeling stupid any time this year.

Disclosure: I own shares of BABA, NVDA, and LRCX for the Zacks TAZR Trader portfolio. I own shares of EW and BLUE for the Zacks Healthcare Innovators portfolio.

Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the TAZR Trader and Healthcare Innovators services. Click Follow Author above to receive his latest stock research and macro analysis.

Be sure to follow me on Twitter: @BBolan1

Want more articles from this author? Go to Zacks.com on this article and click the FOLLOW AUTHOR button to get an email each time a new article is published.

Brian Bolan is a Stock Strategist for Zacks.com.

He runs Stocks Under $10 Investor service where he looks for low priced stocks that are seeing positive earnings estimate revisions. This popular service has seen some strong early returns and offers a free trial via the Zacks Ultimate service.

Brian also runs the brand new Zacks Game Changers where he looks for stocks that are disrupting their industries and reaping big gains.

Looking for Ideas with Even Greater Upside?

Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>

Follow us on Twitter:  https://twitter.com/ZacksResearch

Join us on Facebook:  https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/performance

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alibaba Group Holding Limited (BABA) : Free Stock Analysis Report
 
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
 
Sangamo Therapeutics, Inc. (SGMO) : Free Stock Analysis Report
 
bluebird bio, Inc. (BLUE) : Free Stock Analysis Report
 
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research